Literature DB >> 20347907

Assessment of Labrasol/Labrafil/Transcutol (4/4/2, v/v/v) as a non-clinical vehicle for poorly water-soluble compounds after 4-week oral toxicity study in Wistar rats.

J-L Delongeas1, G Vermeil de Conchard, A Beamonte, H Bertheux, C Spire, C Maisonneuve, N Becourt-Lhote, F Goldfain-Blanc, N Claude.   

Abstract

Drug safety research is frequently faced with the challenge of the selection of appropriate vehicles for use in in vivo non-clinical safety assessment studies. Reported here are the results of blend Labrasol, Labrafil and Transcutol, [L/L/T, (4/4/2, v/v/v)], excipients used as bioavailability enhancer and solubilizer for poorly water-soluble compounds and tested daily for 4 weeks by oral route in Wistar rats (10/sex/group) at dose volumes of 5, 10 or 20 mL/kg/day and compared to controls given 20 mL/kg/day of 1% (w/v) hydroxyethylcellulose in purified water. L/L/T was broadly well tolerated at 5 mL/kg/day and lethal at 20 mL/kg/day in 1 of 20 rats treated at this level. Changes in appearance and behaviour were observed from 10 mL/kg/day with volume-related incidence, severity and duration. Reduced feed intake observed from 5 (females) or 10 mL/kg/day (males) resulted in low bodyweights for high volume males only (-11% of controls). There was a volume-related induction of hepatic CYP 1A1/2, 2B1/2 and/or 2E1 subfamilies from 5 mL/kg/day, with high liver weight, centrilobular hepatocellular hypertrophy and high ALT, triglyceride and cholesterol serum values at 20 mL/kg/day. Renal tubular dilation in medulla, cortical cell degeneration/necrosis with granular material in adjacent glomerular spaces, crystal deposits in the inner medulla, papilla and/or renal pelvis, and tubular mineralization, associated with proteinuria and calcium oxalate crystalluria, were observed at 20 mL/kg/day as well as vacuolation in the adrenal cortex, with a sex-dependant localization. According to these results, 5 mL/kg/day was considered as an acceptable volume for further use of L/L/T (4/4/2, v/v/v) blend as a vehicle for poorly water soluble drugs in Wistar rat toxicity studies. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347907     DOI: 10.1016/j.yrtph.2010.03.008

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  7 in total

Review 1.  Preclinical formulations: insight, strategies, and practical considerations.

Authors:  Sanket M Shah; Ankitkumar S Jain; Ritu Kaushik; Mangal S Nagarsenker; Maneesh J Nerurkar
Journal:  AAPS PharmSciTech       Date:  2014-06-12       Impact factor: 3.246

2.  Safety assessment of the pharmacological excipient, diethylene glycol monoethyl ether (DEGEE), using in vitro and in vivo systems.

Authors:  Sonal Srivastava; Sakshi Mishra; Jayant Dewangan; Aman Divakar; Nidhi Gupta; Navodayam Kalleti; Madhav Nilakanth Mugale; Sadan Kumar; Sharad Sharma; Srikanta Kumar Rath
Journal:  Daru       Date:  2019-04-18       Impact factor: 3.117

3.  Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy.

Authors:  Mallesh Kurakula; A M El-Helw; Tariq R Sobahi; Magdy Y Abdelaal
Journal:  Int J Nanomedicine       Date:  2015-01-06

4.  Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies.

Authors:  Zheng Wang; Hong-Jie Mu; Xue-Mei Zhang; Peng-Kai Ma; Sheng-Nan Lian; Feng-Pu Zhang; Sheng-Ying Chu; Wen-Wen Zhang; Ai-Ping Wang; Wen-Yan Wang; Kao-Xiang Sun
Journal:  Int J Nanomedicine       Date:  2015-01-14

5.  Ravuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity.

Authors:  Pollyanna Álvaro Spósito; Ana Lia Mazzeti; Caroline de Oliveira Faria; Julio A Urbina; Gwenaelle Pound-Lana; Maria Terezinha Bahia; Vanessa Furtado Mosqueira
Journal:  Int J Nanomedicine       Date:  2017-05-17

6.  Potent nonopioid antinociceptive activity of telocinobufagin in models of acute pain in mice.

Authors:  Geissy I M C Feitosa; Isabella F Carvalho; Edivaldo B S Coelho; Marla R B Monteiro; Rafael L Medeiros; Ellaine D F Carvalho; Paulo T A Silva; Dóris M F Carvalho; Daniel E A Uchoa; Edilberto R Silveira; Cláudia F Santos; Nilberto R Nascimento; Maria-Denise F Carvalho; Bruno A Cardi; Krishnamurti M Carvalho
Journal:  Pain Rep       Date:  2019-10-08

7.  Effects of spray-drying and choice of solid carriers on concentrations of Labrasol® and Transcutol® in solid self-microemulsifying drug delivery systems (SMEDDS).

Authors:  Liang Li; Tao Yi; Christopher Wai-Kei Lam
Journal:  Molecules       Date:  2013-01-02       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.